NFL Gear Yields Little for Cancer

Only a small proportion of money made from breast cancer-themed football merchandise actually supports efforts to combat the disease.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

FLICKR, MARIANNE O'LEARThe perennial explosion of pink has hit the National Football League (NFL) again this month as part of its campaign to raise funds for the American Cancer Society (ACS). All proceeds from sales of breast cancer-themed merchandise go to the Society's Community Health Advocates National Grants for Empowerment (CHANGE) program, which aims to get more women screened for breast cancer. But “proceeds” actually turns out to be a “shockingly small” slice of the revenue pie from pink NFL merchandise, according to an analysis.

Business Insider reports that $11.25 out of every $100 earned from the gear goes to the cancer nonprofit. The majority of the remaining income goes to retailers, many of which are NFL teams, and manufacturers. Then there are the administrative costs of the ACS, too. “In the end, after everybody has taken their cut, only 8.01 percent of money spent on pink NFL merchandise is actually going towards cancer research,” according to Business Insider.

It's hard to argue that the NFL’s campaign doesn't bring awareness to breast cancer. But some have criticized the league as using the disease to merely market its brand to new fans—a practice that has come to be known as “pinkwashing.” Earlier this month, Ryan Basen wrote at Sports on Earth ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies